Dialysis Performance of the FX CorAL Membrane

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

October 26, 2023

Study Completion Date

December 1, 2024

Conditions
Hemodialysis ComplicationAnticoagulants
Interventions
OTHER

Anticoagulation dosing

Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday

OTHER

Blood sampling

Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.

OTHER

Duration of the dialysis session

Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday

DEVICE

Choice of the hemodialyzer

Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.

Trial Locations (1)

9000

Ghent University Hospital, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER

NCT06203795 - Dialysis Performance of the FX CorAL Membrane | Biotech Hunter | Biotech Hunter